Table 1.

Vascular disrupting agents. Status and use of imaging during recent clinical trials [19,25].

Agent	Imaging Modality	Tumor Type	Trial	References
CA4P (fosbretabulin; Zybrestat)	DCE-MRI or -CT a DWI-MRI b 15O-PET	Lung cancer, ovarian, renal, breast	Phase 1	[26,27,28,29] a [30] b [31]
CA1P (OXi4503)	DCE-MRI 15O-PET	Various	Phase 1	[32]
BNC105P	DCE MRI	Various	Phase 1 21 patients; now in Phase 2	[33]
CYT997	DCE-MRI	Various	31 patients	[34]
AVE8062 (Ombrabulin)	DCE-US	Various, mostly ovarian	25 patients	[35]
NPI2358 (Plinabulin)	DCE-MRI	Various	38 patients	[36]
ZD6126	DCE-MRI	Colon		[37]
EPC2407 (Crolibulin)	DCE- & DWI-MRI	Various	11 subjects, Phase 1	[38]
MN-029 (Denibulin)	DCE-MRI	Various	34 subjects, Phase 1	[39]
DMXAA (ASA404; 5,6-dimethylxanthenone-4-acetic acid; vadimezan)	DCE-MRI	Various	Phase 1	[40]

Abbreviations. DCE: dynamic contrast enhanced; DWI: diffusion weighted imaging; MRI: magnetic resonance imaging, CT: computed tomography; US: ultrasound; PET: positron emission tomography.